FDA approves pembrolizumab for adjuvant treatment of renal cell carcinoma

[FDA]

On November 17, 2021, the Food and Drug Administration approved pembrolizumab (Keytruda, Merck) for the adjuvant treatment of patients with renal cell carcinoma (RCC) at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.


Baca selengkapnya di : http://www.fda.gov...